Research Analysts Offer Predictions for ABEO FY2025 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for Abeona Therapeutics in a report released on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($0.96) for the year, up from their prior estimate of ($1.17). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.11.

A number of other research analysts have also recently issued reports on the company. Stifel Nicolaus decreased their target price on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Alliance Global Partners reiterated a “buy” rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, HC Wainwright lifted their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.50.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $6.45 on Wednesday. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.32. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business’s 50-day moving average price is $5.24 and its two-hundred day moving average price is $5.56. The stock has a market cap of $314.76 million, a PE ratio of -2.40 and a beta of 1.68.

Insider Activity

In related news, Director Mark Alvino sold 8,000 shares of Abeona Therapeutics stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the transaction, the director now directly owns 92,435 shares of the company’s stock, valued at $525,030.80. The trade was a 7.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. lifted its stake in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after acquiring an additional 652,366 shares during the period. Western Standard LLC lifted its stake in Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after buying an additional 386,321 shares during the period. 683 Capital Management LLC lifted its stake in Abeona Therapeutics by 17.3% in the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after buying an additional 116,845 shares during the period. Newtyn Management LLC lifted its stake in Abeona Therapeutics by 26.3% in the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock valued at $2,285,000 after buying an additional 100,000 shares during the period. Finally, Bank of America Corp DE lifted its stake in Abeona Therapeutics by 16.7% in the fourth quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company’s stock valued at $1,473,000 after buying an additional 37,774 shares during the period. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.